AbbVie reports final analysis from Phase III trial of Elahere for ovarian cancer [Yahoo! Finance]
AbbVie Inc. (ABBV)
Last abbvie inc. earnings: 5/1 07:43 am
Check Earnings Report
US:NYSE Investor Relations:
investors.abbvie.com/investor-overview
Company Research
Source: Yahoo! Finance
conjugate (ADC) Elahere against chemotherapy for treating platinum-resistant ovarian cancer (PROC). The randomised trial assessed the therapy's safety and efficacy when given to women with folate receptor alpha (FRa) positive PROC. Its primary endpoint was progression-free survival (PFS), with its secondary endpoints being objective response rate (ORR) and overall survival (OS). The study enrolled 453 subjects who had received up to three previous therapies and exhibited high-grade serous epithelial PROC expressing high FRa levels. The median follow-up of 30.5 months showed that ADC treatment led to a median PFS of 5.59 months compared to 3.98 months for investigator's choice (IC) chemotherapy, decreasing the tumour progressi
Read more
Impact Snapshot
Event Time:
ABBV
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ABBV alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ABBV alerts
High impacting AbbVie Inc. news events
Weekly update
A roundup of the hottest topics
ABBV
News
- AbbVie (ABBV) Stock Moves -0.29%: What You Should Know [Yahoo! Finance]Yahoo! Finance
- Factbox-Widely used drugs on US imports list from Europe [Yahoo! Finance]Yahoo! Finance
- Factbox-Widely used drugs on US imports list from Europe [Yahoo! Finance Canada]Yahoo! Finance Canada
- Oncology Drugs Market Size to Surpass USD 530.39 Billion by 2032, Driven by Advancements in Targeted Therapies and Rising Cancer Incidence – SNS Insider [Yahoo! Finance]Yahoo! Finance
- PESG Report: Silexion Therapeutics' Breakthrough Data Shows SIL204's impact on both Primary Tumors & Metastasis – Signaling a Potential Paradigm Shift in Cancer Treatment [Yahoo! Finance]Yahoo! Finance
ABBV
Earnings
- 1/31/25 - Beat
ABBV
Sec Filings
- 3/18/25 - Form 4
- 3/14/25 - Form 144
- 3/10/25 - Form PRE
- ABBV's page on the SEC website